+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Chronic diseases 4 - Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs



Chronic diseases 4 - Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs



Lancet (North American Edition) 370(9604): 2054-2062



In 2005, a global goal of reducing chronic disease death rates by an additional 2% per year was established. Scaling up coverage of evidence-based interventions to prevent cardiovascular disease in high-risk individuals in low-income and middle-income countries could play a major part in reaching this goal. We aimed to estimate the number of deaths that could be averted and the financial cost of scaling up, above current coverage levels, a multidrug regimen for prevention of cardiovascular disease (a statin, aspirin, and two blood-pressure-lowering medicines) in 23 such countries. Identification of individuals was limited to those already accessing health services, and treatment eligibility was based on the presence of existing cardiovascular disease or absolute risk of cardiovascular disease by use of easily measurable risk factors. Over a 10-year period, scaling up this multidrug regimen could avert 17.9 million deaths from cardiovascular disease (95% uncertainty interval 7.4 million-25.7 million). 56% of deaths averted would be in those younger than 70 years, with more deaths averted in women than in men owing to larger absolute numbers of women at older ages. The 10-year financial cost would be US$47 billion ($33 billion-$61 billion) or an average yearly cost per head of $1.08 ($0.75-1.40), ranging from $0.43 to $0. 90 across low-income countries and from $0.54 to $2.93 across middle-income countries. This package could effectively meet three-quarters of the proposed global goal with a moderate increase in health expenditure.

(PDF emailed within 0-6 h: $19.90)

Accession: 020723259

Download citation: RISBibTeXText

DOI: 10.1016/S0140-6736(07)61699-7


Related references

Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 370(9604): 2054-2062, 2007

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378(9798): 1231-1243, 2011

Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. Lancet. Global Health 2019, 2019

Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. Bmj Global Health 2(4): E000453, 2017

Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. Lancet 372(9642): 940-949, 2008

Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries. Lancet 376(9754): 1785-1797, 2010

Population-based versus high-risk strategies for the prevention of cardiovascular diseases in low- and middle-income countries. Indian Heart Journal 64(5): 439-443, 2013

The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet 390(10113): 2643-2654, 2017

Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387(10013): 61-69, 2016

The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 370(9603): 1929-1938, 2007

World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. Journal of Hypertension 25(8): 1578-1582, 2007

Interventions for the prevention of cardiovascular diseases: a protocol for a systematic review of economic evaluations in low-income and middle-income countries. Bmj Open 6(12): E013668, 2017

Perceptions and impact of plain packaging of tobacco products in low and middle income countries, middle to upper income countries and low-income settings in high-income countries: a systematic review of the literature. Bmj Open 6(3): E010391, 2016

Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations. Cost Effectiveness and Resource Allocation 16: 22, 2018

Chronic diseases 1: The burden and costs of chronic diseases in low-income and middle-income countries. 2007